|LETTER TO EDITOR
|Year : 2017 | Volume
| Issue : 3 | Page : 415-416
Can dexmedetomidine be used as sole maintenance anesthetic agent at standard sedative doses?
Pooja Bihani, Ghansham Biyani, Pradeep Kumar Bhatia, Sadik Mohammed
Department of Anesthesiology and Critical Care, AIIMS, Jodhpur, Rajasthan, India
|Date of Web Publication||11-Sep-2017|
Pradeep Kumar Bhatia
Department of Anesthesiology and Critical Care, AIIMS, Jodhpur, Rajasthan
Source of Support: None, Conflict of Interest: None
|How to cite this article:|
Bihani P, Biyani G, Bhatia PK, Mohammed S. Can dexmedetomidine be used as sole maintenance anesthetic agent at standard sedative doses?. J Anaesthesiol Clin Pharmacol 2017;33:415-6
|How to cite this URL:|
Bihani P, Biyani G, Bhatia PK, Mohammed S. Can dexmedetomidine be used as sole maintenance anesthetic agent at standard sedative doses?. J Anaesthesiol Clin Pharmacol [serial online] 2017 [cited 2021 Mar 8];33:415-6. Available from: https://www.joacp.org/text.asp?2017/33/3/415/168259
We read the article "comparison between propofol and dexmedetomidine on depth of anesthesia: A prospective randomized trial" by Chattopadhyay et al. and would like to contest with the study results.
Dexmedetomidine in standard doses as used by the authors in the present study (1 μg/kg bolus, followed by 0.5 μg/kg/h infusion) is used for conscious sedation in critical care  and for endoscopic procedures. At these doses, it also reduces the requirement of concomitantly administered intravenous or inhalational anesthetic agents (AA), but does not eliminate their need., As quoted by authors, Ramsay and Luterman  used dexmedetomidine as an AA but only when doses were increased to 5-10 mcg/kg and supplemented with local AA for skin grafting.
The methodology of present study is flawed as both propofol and dexmedetomidine were administered at fixed doses and the authors did not explain what they would do if bispectral index (BIS) value rise above the target ranges, and surprisingly not even a single patient in either of the group required supplementation with inhalational or intravenous AA to maintain BIS value in the target range. All patients received intravenous opioids and top ups of muscle relaxants along with the infusion of either of the study drug and authors still ended up concluding dexmedetomidine as sole AA responsible for maintaining the depth of anesthesia in the dexmedetomidine group. Drugs like muscle relaxants also decrease BIS value without affecting consciousness and may mask the signs of the light plane of anesthesia when used with dexmedetomidine. It is evident that the authors were biased to prove the effectiveness of dexmedetomidine as sole AA at standard sedative doses.
Financial support and sponsorship
Conflict of interest
There are no conflicts of interest.
| References|| |
Chattopadhyay U, Mallik S, Ghosh S, Bhattacharya S, Bisai S, Biswas H. Comparison between propofol and dexmedetomidine on depth of anesthesia: A prospective randomized trial. J Anaesthesiol Clin Pharmacol 2014;30:550-4.
] [Full text]
Venn RM, Grounds RM. Comparison between dexmedetomidine and propofol for sedation in the intensive care unit: Patient and clinician perceptions. Br J Anaesth 2001;87:684-90.
Sethi P, Mohammed S, Bhatia PK, Gupta N. Dexmedetomidine versus midazolam for conscious sedation in endoscopic retrograde cholangiopancreatography: An open-label randomised controlled trial. Indian J Anaesth 2014;58:18-24.
] [Full text]
Sen S, Chakraborty J, Santra S, Mukherjee P, Das B. The effect of dexmedetomidine infusion on propofol requirement for maintenance of optimum depth of anaesthesia during elective spine surgery. Indian J Anaesth 2013;57:358-63.
] [Full text]
Piao G, Wu J. Systematic assessment of dexmedetomidine as an anesthetic agent: A meta-analysis of randomized controlled trials. Arch Med Sci 2014;10:19-24.
Ramsay MA, Luterman DL. Dexmedetomidine as a total intravenous anesthetic agent. Anesthesiology 2004;101:787-90.